Allogene Therapeutics
Peter Schow has a extensive work experience in the field of flow cytometry research. Peter currently holds the position of Director-Flow Cytometry Research at Allogene Therapeutics since 2022. Prior to this, they were a Staff Scientist-Cytometry at Alector from 2019 to 2022. Peter also worked as the Manager-Flow Cytometry Core Facility at Rinat Neuroscience from 2016 to 2019, and as a Scientist at Amgen from 2010 to 2016. Before that, they held the position of Director-Flow Cytometry Core Facility at Dana-Farber Cancer Institute from 2005 to 2010, and Manager-Flow Cytometry Core Facility at Genentech from 1998 to 2003. Peter also served as the Manager of Flow Cytometry Core Facility at UC Berkeley from 1992 to 1998, and as an Operator-Flow Cytometry Core Facility at Dana-Farber Cancer Institute from 1986 to 1992.
Peter Schow attended Roger Williams University from 1982 to 1986 and obtained a Bachelor of Science degree in Biology.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.